High rate of HSV-1 reactivation in invasively ventilated COVID-19 patients: Immunological findings

PLoS One. 2021 Jul 1;16(7):e0254129. doi: 10.1371/journal.pone.0254129. eCollection 2021.

Abstract

SARS-CoV-2 infection can lead to severe acute respiratory distress syndrome with the need of invasive ventilation. Pulmonary herpes simplex-1 (HSV-1) reactivation in invasively ventilated patients is a known phenomenon. To date very little is known about the frequency and the predisposing factors of HSV-1 reactivation in COVID-19. Therefore, we evaluated our cohort of invasively ventilated COVID-19 patients with severe pneumonia for HSV-1 in respiratory specimens and combined these results with functional immunomonitoring of the peripheral blood. Tracheal secretions and bronchial lavages were screened by PCR for HSV-1 positivity. Comprehensive immunophenotyping and quantitative gene expression analysis of Interferon-stimulated genes (IFI44L, MX1, RSAD2, ISIG15 and IFIT1) and IL-1 beta were performed in whole blood. Time course of infection beginning at symptom onset was grouped into three phases ("early" phase 1: day 1-10, "middle" phase 2: day 11-30 and "late" phase 3: day 31-40). Pulmonary HSV-1 reactivation was exclusively observed in the later phases 2 and 3 in 15 of 18 analyzed patients. By FACS analysis a significant increase in activated CD8 T cells (CD38+HLADR+) in phase 2 was found when compared with phase 1 (p<0.05). Expression of Interferon-stimulated genes (IFI44L, RSAD2 ISIG15, MX1, IFIT1) was significantly lower after HSV-1 detection than before. Taken together, reactivation of HSV-1 in the later phase of SARS-CoV-2- infection occurs in parallel with a drop of antiviral innate responsiveness as shown by decreased expression of Interferon-stimulated genes and a concurrent increase of highly activated CD38+HLADR+ CD8 T cells.

MeSH terms

  • Aged
  • Aged, 80 and over
  • COVID-19 / complications
  • COVID-19 / immunology
  • COVID-19 / therapy*
  • Female
  • Herpes Simplex / etiology*
  • Herpes Simplex / immunology
  • Herpesvirus 1, Human / immunology
  • Herpesvirus 1, Human / isolation & purification
  • Herpesvirus 1, Human / physiology*
  • Humans
  • Immunity, Innate
  • Male
  • Middle Aged
  • Respiration, Artificial* / adverse effects
  • SARS-CoV-2 / immunology
  • SARS-CoV-2 / isolation & purification
  • Virus Activation*

Grants and funding

The authors received no specific funding for this work.